Please assess the completion status of the following clinical trial:

Trial Title: Study of Losartan in the Treatment of NAFLD in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) \> 85th% for age and gender~* History of definite or borderline nonalcoholic steatohepatitis (NASH) diagnosed by liver biopsy using NASH Clinical Research Network (CRN) criteria~* At least 2 months of attempted lifestyle changes after liver biopsy~* Current ALT ≥ 3 times normal (69 U/L for girls, 78 U/L for boys) at enrollment~* Glomerular filtration rate (GRF) \> 90~* Weight ≥ 62.5 kg~Exclusion Criteria:~* Other chronic illness requiring daily medication (except medications for mild mental illness, acid reflux, allergies, stable attention deficit hyperactivity disorder (ADHD), or asthma)~* Supplement or anti-oxidant therapy within past 2 weeks~* Renal insufficiency~* Cirrhosis and liver synthetic dysfunction (International Normalized Ratio ≥ 1.5)~* History of hypotension~* Diabetes (or fasting glucose \> 125 mg/dL)~* Acute illness within past 2 weeks prior to enrollment (fever \> 100.4ºF)~* Pregnancy

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Losartan then Placebo (Type: EXPERIMENTAL): 0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks then placebo pill for 8 weeks
- Sugar pill (Type: EXPERIMENTAL): placebo pill taken for 8 weeks then 0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).